These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9512101)

  • 21. Iontophoretic evaluation of vascular reactivity to acetylcholine in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Marasini B; Conciato L
    Clin Rheumatol; 2001; 20(6):451-2. PubMed ID: 11771535
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinically normal skin becomes sclerodermatous when transplanted into a sclerodermatous area.
    Herrick AL; Marcuson R; Freemont AJ; Jayson MI
    Br J Rheumatol; 1992 Oct; 31(10):707-9. PubMed ID: 1393379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous fibrinolytic activity in scleroderma.
    Lotti T; Cerinic MM; Marmugi D; Fabbri P
    Clin Exp Rheumatol; 1985; 3(3):249-53. PubMed ID: 4053443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular and molecular mechanisms in the pathophysiology of systemic sclerosis.
    Hua-Huy T; Dinh-Xuan AT
    Pathol Biol (Paris); 2015 Apr; 63(2):61-8. PubMed ID: 25818311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microangiopathy and microcirculatory disorders in progressive systemic sclerosis (PSS).
    Guseva NG; Much ES; Sysoev VF
    Bibl Anat; 1973; 11():347-51. PubMed ID: 4789061
    [No Abstract]   [Full Text] [Related]  

  • 26. Vascular disease in scleroderma.
    Wigley FM
    Clin Rev Allergy Immunol; 2009 Jun; 36(2-3):150-75. PubMed ID: 19067252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The genetics of systemic sclerosis: an update.
    Romano E; Manetti M; Guiducci S; Ceccarelli C; Allanore Y; Matucci-Cerinic M
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S75-86. PubMed ID: 21586222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating microangiopathy in systemic sclerosis: what have we learnt and what is left to discover?
    Cutolo M; Sulli A; Smith V
    Expert Rev Clin Immunol; 2011 Jul; 7(4):395-7. PubMed ID: 21790279
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.
    Sunderkötter C; Riemekasten G
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii33-5. PubMed ID: 16987831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibroblast and endothelial apoptosis in systemic sclerosis.
    Jun JB; Kuechle M; Harlan JM; Elkon KB
    Curr Opin Rheumatol; 2003 Nov; 15(6):756-60. PubMed ID: 14569206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic sclerosis: a collagen or microvascular disease?
    Jayson MI
    Br Med J (Clin Res Ed); 1984 Jun; 288(6434):1855-7. PubMed ID: 6428575
    [No Abstract]   [Full Text] [Related]  

  • 32. Lung involvement in systemic sclerosis.
    Silver RM; Miller KS
    Rheum Dis Clin North Am; 1990 Feb; 16(1):199-216. PubMed ID: 2406808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular disease in progressive systemic sclerosis (scleroderma).
    Norton WL; Nardo JM
    Ann Intern Med; 1970 Aug; 73(2):317-24. PubMed ID: 4916764
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathogenesis of systemic sclerosis: a vascular hypothesis.
    Campbell PM; LeRoy EC
    Semin Arthritis Rheum; 1975 May; 4(4):351-68. PubMed ID: 1135634
    [No Abstract]   [Full Text] [Related]  

  • 35. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages.
    Kräling BM; Maul GG; Jimenez SA
    Pathobiology; 1995; 63(1):48-56. PubMed ID: 7546275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scleroderma: pathogenic factors and current management.
    Penny R
    Aust N Z J Med; 1978; 8 Suppl 1():143-8. PubMed ID: 365159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impaired lymphangiogenesis due to excess vascular endothelial growth factor-D/Flt-4 signalling in the skin of patients with systemic sclerosis.
    Honda N; Jinnin M; Kajihara I; Makino T; Fukushima S; Ihn H
    Br J Dermatol; 2010 Oct; 163(4):776-80. PubMed ID: 20491763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body composition and microvascular damage in systemic sclerosis patients.
    Gigante A; Rosato E; Muscaritoli M
    J Endocrinol Invest; 2021 Jan; 44(1):205-206. PubMed ID: 32683616
    [No Abstract]   [Full Text] [Related]  

  • 39. The vascular, inflammatory, and fibrotic components in scleroderma skin.
    Fleischmajer R; Perlish JS
    Monogr Pathol; 1983; 24():40-54. PubMed ID: 6350857
    [No Abstract]   [Full Text] [Related]  

  • 40. Oxidative stress, microvascular dysfunction, and scleroderma: an association with potential therapeutic implications, a commentary on "Postocclusive reactive hyperemia inversely correlates with urinary 15-F2t-isoprostane levels in systemic sclerosis".
    Chung CP; Avalos I; Stein CM
    Free Radic Biol Med; 2006 May; 40(10):1698-9. PubMed ID: 16678008
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.